title: Clinical and instrumental evaluation of the efficacy of a new depigmenting agent containing a combination of a retinoid, a phenolic agent and an antioxidant for the treatment of solar lentigines.
abstract: BACKGROUND
  Solar lentigines are common benign macular hyperpigmented lesions localized on sun-exposed areas.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of a new depigmenting agent containing a retinoid (retinaldehyde), a new phenolic agent (4-(1-phenylethyl)-resorcinol) and a reducing agent (δ-tocopheryl-β-D-glucopyranoside) in the topical treatment of solar lentigines.
  
  
  METHODS
  Twenty patients with solar lentigines of the face and hands applied the depigmenting agent on each lentigo once daily for 12 weeks. The outcome was evaluated at 45 days (T1) and 3 months (T2) after the end of treatment compared to baseline (T0) by means of clinical evaluation, Mexameter® and Visioface devices for digital and ultraviolet computerized image analysis of skin color as well as in vivo reflectance confocal microscopy.
  
  
  RESULTS
  Image analysis and confocal laser reflectance microscopy showed that hyperpigmentation was significantly reduced at T2 compared to baseline and to controls.
  
  
  CONCLUSIONS
  The study treatment was well tolerated and showed significant improvement in the depigmentation of solar lentigines.
authors: Department of Dermatology, San Gallicano Institute IRCCS, Rome, Italy.
authors: Norma
authors: N
authors: Cameli
authors: Elva
authors: E
authors: Abril
authors: Marina
authors: M
authors: Agozzino
authors: Maria
authors: M
authors: Mariano
mesh_terms: D000328:Adult; D004338:Drug Combinations; D005148:Facial Dermatoses / Q000188:drug therapy*; D005260:Female; D005960:Glucosides / Q000627:therapeutic use; D006229:Hand Dermatoses / Q000188:drug therapy*; D006801:Humans; D017495:Hyperpigmentation / Q000188:drug therapy* / Q000473:pathology; D007091:Image Processing, Computer-Assisted; D007911:Lentigo / Q000188:drug therapy* / Q000473:pathology; D018613:Microscopy, Confocal; D008875:Middle Aged; D019163:Reducing Agents / Q000627:therapeutic use; D012118:Resorcinols / Q000627:therapeutic use; D012172:Retinaldehyde / Q000627:therapeutic use; D062327:Skin Lightening Preparations / Q000627:therapeutic use*; D024505:Tocopherols / Q000627:therapeutic use
chemical_list: C000604904:4-(1-phenylethyl)resorcinol; D004338:Drug Combinations; D005960:Glucosides; D019163:Reducing Agents; D012118:Resorcinols; D062327:Skin Lightening Preparations; C000604905:delta-tocopheryl glucopyranoside; D024505:Tocopherols; D012172:Retinaldehyde